Conceivably, interruption of this feedback pathway by the pharmacologic targeting RhoA could provide a means to reset type I IFN activation in a manner that would therapeutically beneficial in lupus but preserve necessary physiologic responses to infection. The gene discussed is RHOA; the disease is infection.